Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib for CMR in Chronic Phase CML
NCT01342679Phase 2Completed
- Sponsor
- Kanto CML Study Group
- Start
- Apr 2011
- Primary completion
- Mar 2013
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in chronic myeloid leukemia (CML), sponsored by Kanto CML Study Group. Started Apr 2011; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01342679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01342679.